The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
Top Cited Papers
- 4 September 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 9 (10), 579-590
- https://doi.org/10.1038/nrclinonc.2012.150
Abstract
Allogeneic haematopoietic stem-cell transplantation (HSCT) is frequently applied as part of the treatment in patients with acute myeloid leukaemia (AML) in their first or subsequent remission. Allogeneic HSCT reduces relapse, but nonrelapse mortality and morbidity might counterbalance this beneficial effect. Here, we review recent studies reporting new disease-specific prognostic markers, in addition to allogeneic-HSCT-related risk factors, which can be assessed at specific time points during treatment. We propose risk assessment as a dynamic process during treatment, incorporating both disease-related and transplant-related factors for the decision to proceed either to allogeneic HSCT or to apply a nontransplant strategy. We suggest that allogeneic HSCT might be favoured if the projected disease-free survival is expected to improve by at least 10% based on an individual's risk assessment. The approach requires initial disease risk assessment, identifying a sibling or unrelated donor soon after diagnosis and the incorporation of time-dependent risk factors, all within the context of an integrated therapeutic management approach.Keywords
This publication has 130 references indexed in Scilit:
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2012
- Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDSBone Marrow Transplantation, 2012
- Donor Characteristics Affecting Graft Failure, Graft-versus-Host Disease, and Survival after Unrelated Donor Transplantation with Reduced-Intensity Conditioning for Hematologic MalignanciesTransplantation and Cellular Therapy, 2011
- Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and ComorbiditiesTransplantation and Cellular Therapy, 2011
- DNMT3AMutations in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2010
- Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationThe New England Journal of Medicine, 2010
- Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor StudyLeukemia, 2010
- Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) in Single and Multiple Institutions: Limitations and InferencesTransplantation and Cellular Therapy, 2009
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete RemissionJAMA, 2009
- What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation?Best Practice & Research Clinical Haematology, 2008